Orthofix Medical has launched a synthetic bioactive bone graft solution, Opus BA, for cervical and lumbar spine fusion procedures.
With the full market launch of the solution, the company has expanded its synthetic bone growth offerings.
Go deeper with GlobalData
Acting as a scaffold, Opus BA allows bone to grow across the surface and is reabsorbed and replaced with natural bone while healing.
The solution is available in putty and strip formulations and can be used to fill bone voids or gaps in the skeletal system.
The company stated that Opus BA is hydrated with autogenous bone marrow or autograft with saline.
It is claimed to be moldable and useful for versatile applications.
Orthofix global spine president Kevin Kenny said: “We recognise that each bone substitute has its own unique advantages and surgeons have different preferences when evaluating the use of autologous, allogeneic or synthetic bone graft materials for their patients.
“The addition of Opus BA is another example of our commitment to providing surgeons with a wide range of solutions, so they can select the best bone substitute for each patient.”
The osteoconductive matrix of Opus BA is created using a specific mix of components, including bioactive glass, carbonate apatite bone mineral and Type 1 Collagen carrier.
These materials have the ability to stimulate the formation, growth and resorption of bone.
Orthofix currently markets and distributes Collage osteoconductive scaffold, FiberFuse Advanced moldable allograft, and Trinity Elite and Trinity Evolution allografts with viable cells.
The company’s portfolio also includes AlloQuent structural allograft, Opus Mg Set bone void filler, the O-Genesis graft delivery system, the FiberFuse Strip preformed allograft and VersaShield amniotic membrane.
